A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
A Multicenter, Randomized, Double Blind, Double Dummy Controlled Study to Assess the Tolerability of an Increased Dose of Enteric Coated MPA After Conversion From MMF in Renal Transplant Recipients Who Required MMF Dose Reductions Due to Gastrointestinal Symptoms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Novartis
-
-
California
-
Los Angeles, California, United States, 90033
- Novartis
-
Los Angeles, California, United States, 90057
- Novartis
-
Los Angeles, California, United States, 90095
- Novartis
-
Orange, California, United States, 92868
- Novartis
-
San Diego, California, United States, 92123
- Novartis
-
San Francisco, California, United States, 94143
- Novartis
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- Novartis
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Novartis
-
-
Florida
-
Orlando, Florida, United States, 32804
- Novartis
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Novartis
-
-
Maine
-
Portland, Maine, United States, 04102
- Novartis
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Novartis
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Novartis
-
Boston, Massachusetts, United States, 02215
- Novartis
-
Springfield, Massachusetts, United States, 01107
- Novartis
-
-
Michigan
-
Detroit, Michigan, United States, 48236
- Novarits
-
-
New York
-
New York, New York, United States, 10032
- Novartis
-
New York, New York, United States, 10029
- Novartis
-
New York, New York, United States, 10065
- Novartis
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Novartis
-
Durham, North Carolina, United States, 27710
- Novartis
-
Greenville, North Carolina, United States, 27834
- Novartis
-
Winston-Salem, North Carolina, United States, 27103
- Novartis
-
-
North Dakota
-
Fargo, North Dakota, United States, 58123
- Novarits
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Novartis
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Novartis
-
Portland, Oregon, United States, 97239
- Novartis
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Novartis
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Novartis
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Novartis
-
-
Texas
-
Dallas, Texas, United States, 75230
- Novartis
-
Houston, Texas, United States, 77054
- Novartis
-
Temple, Texas, United States, 76508
- Novartis
-
-
Utah
-
Murray, Utah, United States, 84107
- Novartis
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Novartis
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Novartis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Recipients of first or second cadaveric, living unrelated or living related kidney transplant.
- Patients on a reduced daily dose (500mg to 1500mg) of MMF with existing but tolerable and controlled gastrointestinal symptoms.
- Recipients who are at least 4 weeks post renal transplantation with stable renal function.
Exclusion criteria:
- Multi organ transplant or previous transplant with organ other than kidney
- History of GI disorder prior to transplant
- Evidence of GI disorder induced by infection, underlying medical condition, or con med other than MMF
- Modification of GI med or MMF dose within one week
- Evidence of graft rejection, treatment of acute rejection, unstable renal function within 1 week of (baseline) visit
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Enteric-coated Mycophenolate Acid
Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo.
1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose).
The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
|
Other Names:
|
|
Active Comparator: Mycophenolate Mofetil
Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid.
The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Response (Yes/no)
Time Frame: 6 weeks
|
The primary variable was the response (yes/no) with positive response being defined as an increase of 360 mg/day enteric-coated mycophenolate acid (MPA)from the baseline daily dose, tolerated and maintained for a 4 week duration until the end of the study (Week 6).
Tolerability was defined as the overall assessment of improvement or no change in the intensity of physician assessed gastrointestinal (GI) symptoms at end of study as reported on the physician administered evaluation of GI symptomatology.
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Daily Doses (mg) of Enteric-coated Mycophenolate Acid (MPA) and Mycophenolate Mofetil (MMF) by Treatment Duration Intervals
Time Frame: Baseline and week 4 to week 6
|
The average daily doses of enteric-coated mycophenolate acid (MPA) and mycophenolate mofetil (MMF) at baseline and during the last 2 weeks of treatment.
1000 mg MMF = 720 mg enteric-coated MPA (MPA equivalent dose).
|
Baseline and week 4 to week 6
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CERL080AUS67
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.